36th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium (ENA2024)
Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is proud to have attended the 36th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium (ENA2024) in Barcelona, Spain on the 23rd – 25th of October 2024. ENA is an international drug development and translational research meeting, focusing on preclinical and phase I studies and facilitating in depth discussion on the latest developments in cancer targets and drugs.
Representing Physiomics were Head of Business Development, Hayley Close, and Biosimulation Scientist, Dr Lea Sta, who engaged with the audience of academics, scientists and pharmaceutical industry leaders, including both existing and potential new clients, to discuss the transformative applications of modelling and simulation in oncology drug development.
Additionally, Physiomics presented the latest results from our PARTNER trial, led by the Portsmouth Technology Trials Unit, in the poster titled “Data analysis and model evaluation of chemotherapy-induced neutropenia: Results from the PARTNER trial.“. This observational study gathered crucial data from prostate cancer patients treated with docetaxel, helping to validate our personalised dosing tool and confirm the ability of the tool to predict levels and timing of episodes of neutropenia associated with use of docetaxel, which can lead to serious side effects for patients.
For more information about Physiomics’ services or the work presented at EORTC-NCI-AACR 2024, please visit www.physiomics.co.uk.
Enquiries:
Physiomics plc
Dr Peter Sargent, Chief Executive Officer, +44 (0)1865 784 980
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc combines cutting edge PKPD and QSP modelling techniques with cancer biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design of pre-clinical and clinical studies.
Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.